Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.79 |
| ▸ | CA1 | P00915 | 1/20 | 0.79 |
| ▸ | CA2 | P00918 | 1/20 | 0.79 |
| ▸ | CA4 | P22748 | 1/20 | 0.79 |
| ▸ | CA9 | Q16790 | 1/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036360 | 1.00 | PTGS2 (1.00) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL17378101 | 0.91 | PTGS2 (0.84) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL5106356 | 0.91 | PTGS2 (0.86) | PTGS2PTGS1 | |
| SCHEMBL838523 | 0.90 | PTGS2 (0.86) | PTGS2PTGS1HRH4 | |
| SCHEMBL17378100 | 0.88 | PTGS2 (0.79) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL17378079 | 0.88 | PTGS2 (0.79) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL839556 | 0.88 | PTGS2 (0.86) | PTGS2PTGS1HRH4 | |
| SCHEMBL17369608 | 0.88 | PTGS2 (0.79) | PTGS2CA12CA1CA2CA4 | |
| SCHEMBL5797033 | 0.88 | PTGS2 (1.00) | PTGS2PTGS1HRH4 | |
| SCHEMBL14346071 | 0.88 | PTGS2 (0.81) | PTGS2PTGS1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126617-A | Piezoelectric agonists for preventing or reversing abnormal amyloid deposition | 东芬兰大学 | 2022-03-01 | — | — | CN | disclosed |
| WO-2014176460-A1 | METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS | CHAU DAVID T (US) | 2014-10-30 | — | — | WO | disclosed |
| US-8486922-B2 | Composition | CHEN CHIEN-HUNG (TW) | 2013-07-16 | — | — | US | disclosed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110281829-A1 | NOVEL COMPOSITION | IPINTL, LLC (US) | 2011-11-17 | — | — | US | disclosed |
| US-7628975-B2 | kits for discriminating between COX-1 and COX-2 activity; screening for a tumor, monitoring anticancer treatment or antiinflammatory treatment; less invasive; 2-arachidonylglycerol is a substrate of the COX-2 enzyme, but not COX-1 | VANDERBILT UNIVERSITY (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1307585-B1 | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING COX-2 ACTIVITY AND 2-ARACHIDONYLGLYCEROL METABOLITES | UNIV VANDERBILT (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-1307538-B1 | DETECTION OF COX-2 ACTIVITY AND ANANDAMIDE METABOLITES | UNIV VANDERBILT (US) | 2009-01-07 | — | — | EP | disclosed |
| US-7189504-B2 | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites | VANDERBILT UNIVERSITY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20060110786-A1 | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylgycerol metabolites | VANDERBILT UNIVERSITY | 2006-05-25 | — | — | US | disclosed |
| US-20020106707-A1 | Compositions and methods for detecting and quantifying COX-2 activity and anandamide metabolites | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-08-08 | — | — | US | disclosed |
| US-20020064804-A1 | Compositions and methods for detecting and quantifying COX-2 activity and 2-arachidonylglycerol metabolites | VANDERBILT UNIVERSITY | 2002-05-30 | — | — | US | disclosed |